602 results on '"Myelodysplastic Syndromes"'
Search Results
2. Researchers from Tel Aviv University School of Medicine Publish New Studies and Findings in the Area of Myelodysplastic Syndromes (How we diagnose Myelodysplastic syndromes)
3. Research Results from Dana-Farber Cancer Institute Update Knowledge of Myelodysplastic Syndromes (Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study)
4. Reports on Myelodysplastic Syndromes from National Taiwan University Hospital Provide New Insights (Distinct Genetic Landscapes and Their Clinical Implications In Younger and Older Patients With Myelodysplastic Syndromes)
5. Data on Myelodysplastic Syndromes Detailed by a Researcher at Zagazig University (Irisin in myelodysplastic syndromes: connecting inflammation, oncogenesis, and atherogenesis)
6. Study Data from University of Kansas Update Understanding of Myelodysplastic Syndromes (Outcomes With Allogeneic Hematopoietic Stem Cell Transplantation In Tp53-mutated Myelodysplastic Syndrome: a Systematic Review and Meta-analysis)
7. Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl[R] (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
8. Findings from Zhejiang University Update Understanding of Myelodysplastic Syndromes (Ectopic Expression of the Transcription Factor Onecut3 Drives a Complex Karyotype In Myelodysplastic Syndromes)
9. Researcher at Tel Aviv University Publishes New Data on Myelodysplastic Syndromes (Analyzing Blood Cells of High-Risk Myelodysplastic Syndrome Patients Using Interferometric Phase Microscopy and Fluorescent Flow Cytometry)
10. Clinical Hospital Merkur Researchers Discuss Research in Myelodysplastic Syndromes (Flow Cytometry in Myelodysplastic Syndrome- Correlation With Cytomorphology Results)
11. FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
12. Investigators from Virginia Commonwealth University Release New Data on Myelodysplastic Syndromes (Myelodysplasia Cutis Masquerading As Granulomatous Dermatitis)
13. Research Data from University of Wisconsin School of Medicine and Public Health Update Understanding of Myelodysplastic Syndromes ('Transplant Changes Your Life': Communication Strategies of Transplant Hematologists in High Risk Decision Making
14. Servier Presents Updated Results for TIBSOVO (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress
15. Myelodysplastic syndromes
16. 'Soluble Cd33 For Treating Myelodysplastic Syndromes (Mds)' in Patent Application Approval Process (USPTO 20230348555)
17. Reports Outline Myelodysplastic Syndromes Study Findings from Thomas Jefferson University (Neutrophilic Panniculitis Associated With Myelodysplastic Syndrome/Myeloproliferative Neoplasm: A Case Report and Literature Review)
18. Research on Myelodysplastic Syndromes Reported by a Researcher at Oregon Health & Science University (OHSU) (Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes)
19. Researcher's Work from Shanghai Jiao Tong University School of Medicine Focuses on Myelodysplastic Syndromes [Interpretation of clinical practice guidelines for myelodysplastic syndrome (version 1, 2023) of National Comprehensive Cancer ...]
20. U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl(r) (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
21. Findings from Yale University School of Medicine Provide New Insights into Myelodysplastic Syndromes (Novel Approaches and Future Directions In Myelodysplastic Syndrome Treatment)
22. Reports from University of Texas MD Anderson Cancer Center Add New Data to Research in Myelodysplastic Syndromes [Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in ...]
23. National Institutes of Health Researcher Publishes New Studies and Findings in the Area of Myelodysplastic Syndromes (Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes)
24. Bristol Myers Squibb Gains US FDA Acceptance for Priority Review of Supplemental Biologics License Application for Reblozyl as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes
25. Myelodysplastic syndromes disable human CD271+VCAM1+CD146+ niches supporting normal hematopoietic stem/progenitor cells (Updated April 10, 2023)
26. Patent Issued for Soluble CD33 for treating myelodysplastic syndromes (MDS) (USPTO 11584787)
27. NEW OPTIMISM ON MYELODYSPLASTIC SYNDROMES
28. FOUNDATION GRANT FUELS SYLVESTER RESEARCHER'S NOVEL WORK ON MYELODYSPLASTIC SYNDROMES
29. Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes
30. Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes
31. Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes
32. Study Data from Bristol-Myers Squibb Company Update Understanding of Myelodysplastic Syndromes (Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis)
33. New Myelodysplastic Syndromes Data Has Been Reported by a Researcher at Fudan University (Characterization of Serous Cell-Free DNA in Myelodysplastic Syndromes)
34. Patent Application Titled 'Venetoclax Dosing Regimens For Use In Treating Myelodysplastic Syndromes In Combination With Azacitidine' Published Online (USPTO 20220378811)
35. THE MDS HUB CONTINUES TO ENHANCE GLOBAL KNOWLEDGE OF MYELODYSPLASTIC SYNDROMES THROUGHOUT THROUGH KEY CONGRESS COVERAGE IN 2022
36. Wakayama Medical University Researchers Publish New Data on Myelodysplastic Syndromes (Renal Leukemic Infiltration Overlapping Acute Focal Bacterial Nephritis during Myelodysplastic Syndrome: An Autopsy Case Report)
37. Karyopharm Therapeutics' eltanexor receives new regulatory designations to treat myelodysplastic syndromes
38. Karyopharm Therapeutics' eltanexor receives new regulatory designations to treat myelodysplastic syndromes
39. Research Conducted at H. Lee Moffitt Cancer Center and Research Institute Has Provided New Information about Myelodysplastic Syndromes (Prognostic Scoring Systems and Risk Stratification In Myelodysplastic Syndrome: Focus On Integration of ...)
40. Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes
41. ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
42. Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
43. Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
44. MDS Hub maintains its focus on raising the levels of global knowledge of myelodysplastic syndromes in 2021
45. Astex Pharmaceuticals presents survival data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI(r) (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes
46. Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes
47. Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes
48. Data on Myelodysplastic Syndromes Described by Researchers at Massachusetts General Hospital (Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal ...)
49. Study Data from Massachusetts General Hospital Update Knowledge of Myelodysplastic Syndromes [Emerging Immuno-oncology Targets In Myelodysplastic Syndromes (Mds)]
50. New Myelodysplastic Syndromes Study Findings Reported from Dana-Farber Cancer Institute (A Systematic Review of Higher-risk Myelodysplastic Syndromes Clinical Trials To Determine the Benchmark of Azacitidine and Explore Alternative Endpoints ...)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.